Xianruida Medical-B (06669) is expected to have a net loss of no more than 80.9 million yuan, year-on-year profit to loss

According to Zhitong Finance App, Xianruida Medical-B (06669) announced that the Group expects to record a net loss of no more than RMB 80.9 million for the six months ending June 30, 2026 (the relevant period), while the six months ending June 30, 2025 (past period) will record a net profit of approximately RMB 88.6 million. Expected results will be converted from net profit for the previous period to net loss for the relevant period, mainly due to the termination of the US clinical trial program (clinical project) of the AcoArt Litos® paclitaxel® paclitaxel coated percutaneous angioplasty (PTA) balloon catheter (this product), which resulted in a one-time non-cash impairment loss (i.e. capitalized R&D expenses for clinical projects) and a one-time provision for termination of the clinical project, totaling approximately RMB 151 million. After review by management, given that future changes in the product pipeline and local market dynamics in the US may limit the profitability of this product, the Group has terminated the clinical project; management believes that allocating resources to other future product pipelines is commercially preferable. The Group is exploring new overseas pipelines with its business partners and will provide further details in due course.